KALA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.55%, SMA50 -28.98%, SMA200 -91.06%). The stock’s 14-day RSI is 37.09 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.16% below its high and over 7.71% above its low. Average 10-day trading volume of 275.04 thousand shares is below the 3-month average of 338.78 thousand, indicating normal recent market interest.

KALA BIO, Inc. generated EPS of -$5.94 over the past year. Five-year average earnings growth is 40.66%. The latest quarter delivered EPS of -$21.32. The next quarter is forecast at $nan. Next year's EPS is expected at $34.23. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $35.00. The high target offers 6040.35% upside. The low target suggests 6040.35% downside. The mean target is $35.00. This offers 6040.35% upside. KALA BIO, Inc. earnings surprise history is a mixed track record. The quarter that ended August 19, 2026, missed forecasts by 255.33%. The prior quarter beat by -98.35%. Over the last six quarters, Apple has recorded several small beats. These include -30.54% in May 14, 2025.

KALA BIO, Inc. has 19.34 million shares outstanding. The public float is 19.34 million shares, elevated short interest at 1.45% of float. This equals 279.43 thousand shares. The short ratio is 1.62 days. Institutional investors hold 0.63% of the float. Insiders own 1.24%. Shah Rajeev M. holds 7.04 million shares, RA CAPITAL MANAGEMENT, L.P. has 7.04 million shares and RA CAPITAL MANAGEMENT, LLC has 4.54 million shares.

KALA BIO, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.93. This means the shares are trading below this model’s fair value.

KALA BIO, Inc. (NASDAQ:KALA) closed at $0.57 USD, gaining $0.01 (1.69%) from the previous close of $0.56. The stock is currently mid-range between its 52-week high and low $0.49 and $1.03 thousand. With a market capitalization of about $11.07 million, KALA BIO, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.29). Key stats such as the average daily volume over the past year has been around 342.96 thousand shares, volume is running light vs its 52-week average. Headquartered in Arlington, MA, KALA BIO, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Avi Minkowitz, the company employs approximately 6 people and listed since July 20, 2017. Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions.

KALA BIO, Inc. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.56, also above market averages.

Our AI price prediction model suggests that KALA BIO, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.9%, with price expected at $0.51 by September 25, 2026, within a range of $0.37 to $0.65 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 10, 2026, with a range of $0.00 to $8.99. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 10, 2027, within a range of $0.00 to $15.07.

KALA BIO, Inc. (NASDAQ:KALA) shares are flat 8.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows KALA BIO, Inc. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.68, suggesting 3338.16% upside. Our AI forecast model points to short-term weakness (-10.9% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.